Skip to main content

Molecular Health Inks Agreement for Precision Medicine Tools With Falco Biosystems

NEW YORK — Molecular Health said on Tuesday that it has signed an agreement to use its MH BRCA and MH Mendel precision medicine software to help Japanese clinical testing firm Falco Biosystems evaluate disease-associated genes for its customers.

Part of Molecular Health's Guide sequencing data-analysis platform for personalized medicine, MH BRCA identifies and reports on inherited variants in BRCA1, BRCA2, and other genes linked to breast and ovarian cancer, while MH Mendel can analyze for a broader range of hereditary disease.

Under the terms of the deal, Falco will sequence patient-provided blood samples and identify genetic variants. Heidelberg, Germany-based Molecular Health will use MH BRCA and MH Mendel to analyze these variant data to distinguish between benign and pathogenic variants.

Molecular Health noted that it will use its MH Dataome platform for molecular and clinical datapoint mining, which integrates the Japanese reference genome ToMMo 3.5KJPNv2, to help with variant filtering and classification.

Additional terms of the deal were not disclosed.